Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Long-Term Investments: 2020-2024

Historic Long-Term Investments for Adma Biologics (ADMA) over the last 5 years, with Dec 2024 value amounting to $5.7 million.

  • Adma Biologics' Long-Term Investments rose 51.19% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year increase of 51.19%. This contributed to the annual value of $5.7 million for FY2024, which is 21.13% up from last year.
  • Adma Biologics' Long-Term Investments amounted to $5.7 million in FY2024, which was up 21.13% from $4.7 million recorded in FY2023.
  • In the past 5 years, Adma Biologics' Long-Term Investments registered a high of $5.7 million during FY2024, and its lowest value of $2.1 million during FY2020.
  • Its 3-year average for Long-Term Investments is $5.0 million, with a median of $4.8 million in 2022.
  • As far as peak fluctuations go, Adma Biologics' Long-Term Investments spiked by 93.04% in 2021, and later dropped by 2.10% in 2023.
  • Over the past 5 years, Adma Biologics' Long-Term Investments (Yearly) stood at $2.1 million in 2020, then skyrocketed by 93.04% to $4.1 million in 2021, then increased by 17.27% to $4.8 million in 2022, then declined by 2.10% to $4.7 million in 2023, then rose by 21.13% to $5.7 million in 2024.